Navigation

Prostate cancer (prevention) - dutasteride [ID75]

Dutasteride for reducing the risk of developing prostate cancer in men who are considered to be at increased risk of developing the disease

Status: Suspended
Expected date of issue: TBC
Referral date: March 2009
Process: STA
Notes:

Cancer reform strategy Batch 3

Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Panagiota Vrouchou
Communications manager: Alice Law
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 18 January 2011
1st appraisal committee meeting: 01 January 2100
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • GlaxoSmithKline (dutasteride)

Patient/carer groups

  • Prostate Cancer Charity

Professional groups

  • British Uro-Oncology Group
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • Hywel Dda Local Health Board
  • Welsh Assembly Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturers

  • None

Relevant research groups

  • MRC Clinical Trials Unit
  • Prostate Action

Evidence Review Group

  • National Institute for Health Research Health Technology Assessment Programme
  • Southampton Health Technology Assessment Centre  

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Top


 

Project history

Date

 

Update

 

27 April 2011

 

NICE has been informed by the manufacturer of dutasteride, GSK, that they have withdrawn their licensing application for the above indication. Therefore this appraisal topic has been suspended and the appraisal committee agenda topic that was due to take place on 14 September 2011 has been cancelled.

NICE will continue to monitor any development and update this webpage if the situation changes.

21 January 2011

 

NICE has re-scheduled the first Appraisal Committee meeting for a number of technology appraisal topics.

In rescheduling these topics we have been careful to maintain our ability to issue timely recommendations.

This appraisal of Dutasteride for reducing the risk of developing prostate cancer is one of the topics that has been identified.

The first appraisal committee discussion will now take place on 14 September 2011.  The second committee meeting (if required) will also be rescheduled.

30 July 2010

 

Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.  Therefore, we now anticipate that the appraisal will begin end of October 2010. The deadline for submissions is expected in approximately mid January 2011.

 

Top


 

Key documents

This page was last updated: 28 February 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.